GT601 / Grit Biotechnology - LARVOL DELTA

Trial in Progress: First in Human Study of GT601, a Next-Generation Neoantigen Cancer Vaccine for Hepatocellular Carcinoma (SITC 2025) - "Any additional data that will be available on a poster that is beyond what was submitted in the abstract is embargoed until Nov. 7, 2025 at 9 a.m. ET."

First-in-human • P1 data • Tumor-specific neoantigens • Hepatocellular Cancer • Oncology • Solid Tumor